Tags

Type your tag names separated by a space and hit enter

Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes.
J Lipid Res. 2020 Jul; 61(7):1065-1074.JL

Abstract

Cardiac dysfunction in T2D is associated with excessive FA uptake, oxidation, and generation of toxic lipid species by the heart. It is not known whether decreasing lipid delivery to the heart can effect improvement in cardiac function in humans with T2D. Thus, our objective was to test the hypothesis that lowering lipid delivery to the heart would result in evidence of decreased "lipotoxicity," improved cardiac function, and salutary effects on plasma biomarkers of cardiovascular risk. Thus, we performed a double-blind randomized placebo-controlled parallel design study of the effects of 12 weeks of fenofibrate-induced lipid lowering on cardiac function, inflammation, and oxidation biomarkers, and on the ratio of two plasma ceramides, Cer d18:1 (4E) (1OH, 3OH)/24:0 and Cer d18:1 (4E) (1OH, 3OH)/16:0 (i.e., "C24:0/C16:0"), which is associated with decreased risk of cardiac dysfunction and heart failure. Fenofibrate lowered plasma TG and cholesterol but did not improve heart systolic or diastolic function. Fenofibrate treatment lowered the plasma C24:0/C16:0 ceramide ratio and minimally altered oxidative stress markers but did not alter measures of inflammation. Overall, plasma TG lowering correlated with improvement of cardiac relaxation (diastolic function) as measured by tissue Doppler-derived parameter e'. Moreover, lowering the plasma C24:0/C16:0 ceramide ratio was correlated with worse diastolic function. These findings indicate that fenofibrate treatment per se is not sufficient to effect changes in cardiac function; however, decreases in plasma TG may be linked to improved diastolic function. In contrast, decreases in plasma C24:0/C16:0 are linked with worsening cardiac function.

Authors+Show Affiliations

Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110 lpeterso@wustl.edu.Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.Division of Biostatistics, Washington University School of Medicine, St. Louis, MO 63110.Division of Endocrinology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32393551

Citation

Peterson, Linda R., et al. "Alterations in Plasma Triglycerides and Ceramides: Links With Cardiac Function in Humans With Type 2 Diabetes." Journal of Lipid Research, vol. 61, no. 7, 2020, pp. 1065-1074.
Peterson LR, Jiang X, Chen L, et al. Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes. J Lipid Res. 2020;61(7):1065-1074.
Peterson, L. R., Jiang, X., Chen, L., Goldberg, A. C., Farmer, M. S., Ory, D. S., & Schaffer, J. E. (2020). Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes. Journal of Lipid Research, 61(7), 1065-1074. https://doi.org/10.1194/jlr.RA120000669
Peterson LR, et al. Alterations in Plasma Triglycerides and Ceramides: Links With Cardiac Function in Humans With Type 2 Diabetes. J Lipid Res. 2020;61(7):1065-1074. PubMed PMID: 32393551.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes. AU - Peterson,Linda R, AU - Jiang,Xuntian, AU - Chen,Ling, AU - Goldberg,Anne C, AU - Farmer,Marsha S, AU - Ory,Daniel S, AU - Schaffer,Jean E, Y1 - 2020/05/11/ PY - 2020/02/10/received PY - 2020/04/15/revised PY - 2021/07/01/pmc-release PY - 2020/5/13/pubmed PY - 2020/5/13/medline PY - 2020/5/13/entrez KW - diastolic function KW - lipid treatments KW - lipotoxicity KW - systolic function SP - 1065 EP - 1074 JF - Journal of lipid research JO - J. Lipid Res. VL - 61 IS - 7 N2 - Cardiac dysfunction in T2D is associated with excessive FA uptake, oxidation, and generation of toxic lipid species by the heart. It is not known whether decreasing lipid delivery to the heart can effect improvement in cardiac function in humans with T2D. Thus, our objective was to test the hypothesis that lowering lipid delivery to the heart would result in evidence of decreased "lipotoxicity," improved cardiac function, and salutary effects on plasma biomarkers of cardiovascular risk. Thus, we performed a double-blind randomized placebo-controlled parallel design study of the effects of 12 weeks of fenofibrate-induced lipid lowering on cardiac function, inflammation, and oxidation biomarkers, and on the ratio of two plasma ceramides, Cer d18:1 (4E) (1OH, 3OH)/24:0 and Cer d18:1 (4E) (1OH, 3OH)/16:0 (i.e., "C24:0/C16:0"), which is associated with decreased risk of cardiac dysfunction and heart failure. Fenofibrate lowered plasma TG and cholesterol but did not improve heart systolic or diastolic function. Fenofibrate treatment lowered the plasma C24:0/C16:0 ceramide ratio and minimally altered oxidative stress markers but did not alter measures of inflammation. Overall, plasma TG lowering correlated with improvement of cardiac relaxation (diastolic function) as measured by tissue Doppler-derived parameter e'. Moreover, lowering the plasma C24:0/C16:0 ceramide ratio was correlated with worse diastolic function. These findings indicate that fenofibrate treatment per se is not sufficient to effect changes in cardiac function; however, decreases in plasma TG may be linked to improved diastolic function. In contrast, decreases in plasma C24:0/C16:0 are linked with worsening cardiac function. SN - 1539-7262 UR - https://www.unboundmedicine.com/medline/citation/32393551/Alterations_in_plasma_triglycerides_and_ceramides:_links_with_cardiac_function_in_humans_with_type_2_diabetes L2 - http://www.jlr.org/cgi/pmidlookup?view=long&pmid=32393551 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.